You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Medtronic
Harvard Business School
McKinsey
Merck

Last Updated: September 25, 2023

Investigational Drug Information for Huperzine A


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Huperzine A?

Huperzine A is an investigational drug.

There have been 16 clinical trials for Huperzine A. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2019.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Supernus Pharmaceuticals, Inc., Biscayne Neurotherapeutics, Inc., and U.S. Army Medical Research and Development Command.

There are two hundred and forty US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Huperzine A
TitleSponsorPhase
The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot StudySecond Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 4
The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot StudyWanbangde Pharmaceutical Group Co., LTDPhase 4
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsySupernus Pharmaceuticals, Inc.Phase 2

See all Huperzine A clinical trials

Clinical Trial Summary for Huperzine A

Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A

See all Huperzine A clinical trials

US Patents for Huperzine A

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Huperzine A ⤷  Try a Trial Heterocyclic flavone derivatives, compositions, and methods related thereto Emory University (Atlanta, GA) ⤷  Try a Trial
Huperzine A ⤷  Try a Trial Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery Corium International, Inc. (Menlo Park, CA) ⤷  Try a Trial
Huperzine A ⤷  Try a Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder Axovant Sciences GmbH (Basel, CH) ⤷  Try a Trial
Huperzine A ⤷  Try a Trial 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides Pfizer Inc. (New York, NY) ⤷  Try a Trial
Huperzine A ⤷  Try a Trial Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications AKER BIOMARINE ANTARCTIC AS (Stamsund, NO) ⤷  Try a Trial
Huperzine A ⤷  Try a Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease Axovant Sciences GmbH (Basel, CH) ⤷  Try a Trial
Huperzine A ⤷  Try a Trial Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors Pfizer Inc. (New York, NY) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Huperzine A

Drugname Country Document Number Estimated Expiration Related US Patent
Huperzine A China CN104487429 2032-07-27 ⤷  Try a Trial
Huperzine A European Patent Office EP2877461 2032-07-27 ⤷  Try a Trial
Huperzine A World Intellectual Property Organization (WIPO) WO2014018741 2032-07-27 ⤷  Try a Trial
Huperzine A Australia AU2017301928 2036-07-27 ⤷  Try a Trial
Huperzine A Australia AU2017301929 2036-07-27 ⤷  Try a Trial
Huperzine A Australia AU2017302305 2036-07-27 ⤷  Try a Trial
Huperzine A Australia AU2017302306 2036-07-27 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Medtronic
Harvard Business School
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.